RxDoctor Payments Data

Nadarajah Nirmalan, MD

Internal Medicine · St Petersburg, FLNPI 1043311699

Payments from drug & device makers

$1,520in general payments, 2019–2025

Across 85 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$636
  • AstraZeneca$212
  • Novo Nordisk$202
  • Lilly USA, LLC$91
  • GSK$65
  • Sumitomo Pharma America, Inc.$63
  • plus $252 from 12 others

What the payments were for

  • Food & beverage$1,520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,520 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$140,583
Medicare patients
197
Services billed
1,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide195$202,803
MounjaroTirzepatide144$162,789
EliquisApixaban185$107,511
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres13$103,496
Enbrel SureclickEtanercept12$102,792
MyrbetriqMirabegron178$75,173
VraylarCariprazine Hcl47$70,655
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$68,594
LinzessLinaclotide91$66,647
TrulicityDulaglutide50$49,402
XifaxanRifaximin12$38,577
FarxigaDapagliflozin Propanediol42$37,161
JanuviaSitagliptin Phosphate45$34,284
MovantikNaloxegol Oxalate86$32,295
GemtesaVibegron51$31,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$202$216,052212 claims
Lilly USA, LLCMounjaro, Trulicity$91$212,191194 claims
AbbVieVraylar, Linzess$636$137,303138 claims
PfizerEliquis$41$107,511185 claims
NovartisSandostatin Lar Depot$21$103,49613 claims
GSKTrelegy Ellipta, Breo Ellipta$65$73,838105 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$212$65,402114 claims
Sumitomo Pharma America, Inc.Gemtesa$63$31,88851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →